Although improved clinical outcome in ovarian cancer has been associated with increased intraepithelial CD3+ and/or CD8+ tumor infiltrating lymphocytes (TILs) [4–6], vaccine strategies aimed at expanding tumor-specific T cells in ovarian cancer patients have demonstrated modest clinical responses [7–9]. This evidence concerns the gene CD8A and ovarian carcinoma.